Ignite Creation Date:
2024-05-06 @ 3:24 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02287428
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2014-10-29
Brief Title:
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
14-362
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
David Reardon MD
Responsible Party Title:
Prinicipal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Institutes of Health NIH | NIH |
| The Ben Catherine Ivy Foundation | OTHER |
| Accelerate Brain Cancer Cure | OTHER |
| Merck Sharp Dohme LLC | INDUSTRY |